GENFF (Genflow Biosciences) Short-Term Debt: $0.00 Mil (As of Dec. 2025)


What is Genflow Biosciences Short-Term Debt?

Genflow Biosciences GENFF +153.27% Short-Term Debt is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Genflow Biosciences's Short-Term Debt for the quarter that ended in Dec. 2025 was $0.00 Mil.

Genflow Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Genflow Biosciences Short-Term Debt Related Terms

Genflow Biosciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Genflow Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genflow Biosciences Short-Term Debt Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.00 0.00 0.00 0.00 0.00

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Genflow Biosciences (GENFF) has a Short-Term Debt of $0.00 Mil as of Dec. 2025.
Is Genflow Biosciences' Short-Term Debt too high?
Genflow Biosciences' current Short-Term Debt is $0.00 Mil.
How does Genflow Biosciences' Short-Term Debt compare to VRTX and REGN?
Genflow Biosciences' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Genflow Biosciences's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genflow Biosciences stock overvalued right now?
Genflow Biosciences (GENFF) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Genflow Biosciences (GENFF), the current Short-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genflow Biosciences Business Description

Other Exchanges GENF:UKWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.